VOLIBRIS 10mg price in UAE

Overview

Welcome to Dwaey, specifically on VOLIBRIS 10mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Ambrisentan.
VOLIBRIS 10mg is available in the market in concentration 10mg/Tablet and in the form of Tablets/Film-coated.

GLAXO GROUP LIMITED is the producer of VOLIBRIS 10mg and it is imported from UK, The most popular alternatives of VOLIBRIS 10mg are listed downward .

Mode Of Action

High affinity endothelin (ETa) receptor subtype antagonist, resulting in inhibition of vasoconstriction.

Indication

Pulmonary Arterial Hypertension

Precaution

Fluid Retention: Peripheral oedema has been observed with ERAs including ambrisentan. It is also a clinical consequence of PAH and worsening PAH. Pulmonary Veno-occlusive Disease: If patients develop acute pulmonary edema during initiation of therapy with vasodilating agents such as Ambrisentan, the possibility of pulmonary veno-occlusive disease should be considered, and if confirmed. Ambrisentan should be discontinued. Hematological Changes: Decreases in hemoglobin concentration and hematocrit have followed administration of other endothelin receptor antagonists and were observed in clinical studies with Ambrisentan. Lactation: Excretion in milk unknown; not recommended

Side Effects

>10% Peripheral edema (17%)
Headache (15%) 1-10% Nasal congestion (6%)
Palpitations (5%)
Constipation (4%)
Dyspnea (4%)
Flushing (4%)
Abdominal pain (3%)
Nasopharyngitis (3%)
Sinusitis (3%)

Contra indication

Ambrisentan may cause fetal harm when administered to a pregnant woman. Ambrisentan is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. Pregnancy must be excluded before the initiation of treatment with Ambrisentan and prevented during treatment and for one month after stopping treatment. Ambrisentan is contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF) including IPF patients with pulmonary hypertension (WHO Group 3).

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Interaction

Cyclosporine Exposure to ambrisentan may be increased (approximately 2-fold). Limit the dosage of ambrisentan to 5 mg daily with coadministration. Rifampin Coadministration was associated with a 2-fold increase in ambrisentan AUC. Use with caution.